Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLB1 | P16278 | 3/20 | 0.36 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13909214 | 0.85 | — | — | |
| SCHEMBL12166506 | 0.74 | CA1 (0.33) | EPHX2 | |
| SCHEMBL19227890 | 0.74 | GLB1 (0.42) | GLB1FUCA1GBA2 | |
| SCHEMBL18892702 | 0.74 | — | — | |
| SCHEMBL14080776 | 0.73 | — | — | |
| SCHEMBL12371362 | 0.72 | — | — | |
| SCHEMBL16499883 | 0.72 | — | — | |
| SCHEMBL17972932 | 0.71 | — | — | |
| SCHEMBL13381569 | 0.71 | EPHX2 (0.32) | GLB1EPHX2 | |
| SCHEMBL12166509 | 0.70 | FUCA1 (0.32) | FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481728-B2 | Process for preparing entecavir and its intermediates | SCINOPHARM TAIWAN, LTD. (TW) | 2013-07-09 | — | — | US | disclosed |
| US-20110201809-A1 | Process for Preparing Entecavir and its Intermediates | SCINOPHARM TAIWAN, LTD. | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201809-A1 | Process for Preparing Entecavir and its Intermediates | ENTPD5, TYMS, TYMP | GLB1 1592/4885FUCA1 3687/4885EPHX2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.